Evidence map›Paper›PMID 36678022›Full record

ArticleNanomaterials (Basel, Switzerland)2023

Nano-Delivery System of Ethanolic Extract of Propolis Targeting

Sirikwan Sangboonruang, Natthawat Semakul, Sureeporn Suriyaprom, Kuntida Kitidee, Jiaranai Khantipongse, Sorasak Intorasoot, Chayada Sitthidet Tharinjaroen, Usanee Wattananandkul, Bordin Butr-Indr, Ponrut Phunpae and 1 more

Open access · goldAbstract read
In one paragraph

Article in Nanomaterials (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
5.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Sirikwan SangboonruangDivision of Clinical Microbiology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand.ORCID 0000-0003-4987-5505
Natthawat SemakulDepartment of Chemistry, Faculty of Sciences, Chiang Mai University, Chiang Mai 50200, Thailand.ORCID 0000-0003-2078-3201
Sureeporn SuriyapromDepartment of Biology, Faculty of Sciences, Chiang Mai University, Chiang Mai 50200, Thailand.
Kuntida KitideeCenter for Research and Innovation, Faculty of Medical Technology, Mahidol University, Salaya, Nakhon Pathom 73170, Thailand.ORCID 0000-0002-6995-3913
Jiaranai KhantipongseOffice of Disease Prevention and Control 1, Chiang Mai 50200, Thailand.
Sorasak IntorasootDivision of Clinical Microbiology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand.ORCID 0000-0002-7137-4750
Chayada Sitthidet TharinjaroenDivision of Clinical Microbiology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand.ORCID 0000-0002-1441-9641
Usanee WattananandkulDivision of Clinical Microbiology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand.ORCID 0000-0002-6648-8972
Bordin Butr-IndrDivision of Clinical Microbiology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand.
Ponrut PhunpaeDivision of Clinical Microbiology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand.
Khajornsak TragoolpuaDivision of Clinical Microbiology, Department of Medical Technology, Faculty of Associated Medical Sciences, Chiang Mai University, Chiang Mai 50200, Thailand.ORCID 0000-0001-8812-5139
Chiang Mai University · THMahidol University · TH

Funding

National Research Council of Thailand N42A650307
6 · The paper itself

Abstract

Tuberculosis (TB) therapy requires long-course multidrug regimens leading to the emergence of drug-resistant TB and increased public health burden worldwide. As the treatment strategy is more challenging, seeking a potent non-antibiotic agent has been raised. Propolis serve as a natural source of bioactive molecules. It has been evidenced to eliminate various microbial pathogens including

Indexed as

Ag85A aptamernano-deliveryniosomespropolistuberculosis

Identifiers

PMID36678022
PMCPMC9861461
OpenAlexW4313827449

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.